2023
Assessment of Treatment-Relevant Immune Biomarkers in Psoriasis and Atopic Dermatitis: Toward Personalized Medicine in Dermatology
Mortlock R, Ma E, Cohen J, Damsky W. Assessment of Treatment-Relevant Immune Biomarkers in Psoriasis and Atopic Dermatitis: Toward Personalized Medicine in Dermatology. Journal Of Investigative Dermatology 2023, 143: 1412-1422. PMID: 37341663, PMCID: PMC10830170, DOI: 10.1016/j.jid.2023.04.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAtopic dermatitisSkin diseasesInflammatory skin diseaseInflammatory skin conditionImmunologic biomarkersImmune biomarkersPersonalized medicineInflammatory dermatosesImmunologic approachesTherapy selectionSkin conditionsSingle-cell RNA sequencingMolecular profilingBiomarkersTissue stainingPsoriasisDermatitisDiseaseDermatologyRNA sequencingMedicineCurettageDermatosesTherapyPersonalized classificationImmune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.Peer-Reviewed Original ResearchConceptsIL-13 expressionBullous pemphigoidImmune-related adverse eventsComplete disease clearancePromising new therapyNovel therapeutic approachesDisease clearanceAdverse eventsTumor immunityTherapeutic approachesNew therapiesConventional treatmentPemphigoidInterleukinTreatmentPatientsExpressionTherapyImmunityClearanceThe effect of baseline eczema or psoriasis on the morphology of cutaneous immune-related adverse events due to immune checkpoint inhibitor therapy
Belzer A, Mortlock R, Pach J, Cohen J, Leventhal J. The effect of baseline eczema or psoriasis on the morphology of cutaneous immune-related adverse events due to immune checkpoint inhibitor therapy. Journal Of The American Academy Of Dermatology 2023, 88: 1198-1200. PMID: 36634749, PMCID: PMC10121758, DOI: 10.1016/j.jaad.2023.01.002.Peer-Reviewed Original Research
2022
Patient perspectives on the lived experience of granuloma annulare
Clark A, Murphy M, King B, Cohen J, Rosenbach M, Barbieri J, Damsky W. Patient perspectives on the lived experience of granuloma annulare. British Journal Of Dermatology 2022, 188: 134-136. PMID: 36689498, DOI: 10.1093/bjd/ljac004.Peer-Reviewed Original ResearchVaccination Recommendations for Psoriasis and Atopic Dermatitis Patients on Biologic Therapy: A Practical Guide.
Fan R, Cohen JM. Vaccination Recommendations for Psoriasis and Atopic Dermatitis Patients on Biologic Therapy: A Practical Guide. The Yale Journal Of Biology And Medicine 2022, 95: 249-255. PMID: 35782480, PMCID: PMC9235258.Peer-Reviewed Original ResearchConceptsAtopic dermatitis patientsBiologic therapyVaccination recommendationsDermatitis patientsTreatment of psoriasisNovel biologic therapiesIL-17IL-23Atopic dermatitisIL-12/23Vaccine administrationClinical dataHealthcare providersAvailable guidelinesPsoriasisTherapyUnique considerationsPatientsPractical guideVaccinationDermatitisTNFαInfectionDermatologistsAdministration
2021
Leveraging behavioral economics to promote treatment adherence: A primer for the practicing dermatologist
Woodbury MJ, Cohen JM, Merola JF, Perez-Chada LM. Leveraging behavioral economics to promote treatment adherence: A primer for the practicing dermatologist. Journal Of The American Academy Of Dermatology 2021, 87: 1075-1080. PMID: 34098000, DOI: 10.1016/j.jaad.2021.05.049.Peer-Reviewed Original ResearchConceptsTreatment adherenceSuboptimal clinical outcomesSuboptimal treatment adherenceQuality of lifeLifestyle modificationMedical therapyClinical outcomesDermatologic patientsPatient adherenceChronic diseasesEfficacious therapyEconomic burdenHealth behaviorsUnmet needScalable interventionsHealth policyAdherenceHealth carePatientsTherapyDiseaseNonadherencePsoriasisDearth of researchPubMed
2020
Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis
Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis. Journal Of The American Academy Of Dermatology 2020, 86: 1080-1091. PMID: 33307146, DOI: 10.1016/j.jaad.2020.12.010.Peer-Reviewed Original ResearchConceptsParadoxical reactionSystematic reviewNecrosis factor α inhibitorsTumor necrosis factor αSpectrum of manifestationsNecrosis factor αAntibody-based therapiesInterleukin-12/23IL-23IL-12/23Clinical featuresCutaneous reactionsEczematous eruptionInflammatory disordersProinflammatory cytokinesΑ inhibitorsRetrospective analysisIL-4RαFactor αPotential mechanismsDermatologyTherapyInhibitorsAntibodiesReaction patterns
2016
Cost-effectiveness of Confirmatory Testing Before Treatment of Onychomycosis
Mikailov A, Cohen J, Joyce C, Mostaghimi A. Cost-effectiveness of Confirmatory Testing Before Treatment of Onychomycosis. JAMA Dermatology 2016, 152: 1-6. PMID: 26716567, DOI: 10.1001/jamadermatol.2015.4190.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdministration, TopicalAlgorithmsCost SavingsCost-Benefit AnalysisDecision Support TechniquesDecision TreesHealth Care CostsHumansHydroxidesNaphthalenesOnychomycosisPeriodic Acid-Schiff ReactionPotassium CompoundsPotentially Inappropriate Medication ListTerbinafineTriazolesConceptsConfirmatory testingOral terbinafineSystemic therapyDirect patient evaluationLiver toxic effectsPatient cost savingsPotassium hydroxide (KOH) stainDisease prevalenceTreatment of onychomycosisConfirmatory diagnostic testingHealth care professionalsPrevalence of diseaseTerbinafine therapyEmpirical therapyPretreatment testingPrimary outcomePatient evaluationSpecific therapyEmpirical treatmentMAIN OUTCOMECare professionalsInternational guidelinesTherapyDiagnostic testingPatient safety